Highly accurate molecular genetic testing for HFE hereditary hemochromatosis: Results from 10 years of blinded proficiency surveys by the College of American Pathologists

Richard Press, Garrett Eickelberg, Thomas J. McDonald, Jaimie Halley, Thomas Long, Laura J. Tafe, Karen E. Weck

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose:The College of American Pathologists offers blinded proficiency testing (PT) for laboratories performing HFE genetic tests for hereditary hemochromatosis (common C282Y and H63D variants). This study used 10 years of PT data to determine laboratory performance for HFE analytical genotyping and clinical interpretation.Methods:Laboratories were graded for accuracy of genotype determination (six possible C282Y/H63D genotypes) and clinical interpretation regarding whether the genotype was likely to have contributed to iron overload in a hypothetical patient.Results:The analytical genotyping error rate was low (0.73%) in 7,663 results (from 257 unique laboratories). Genotyping errors were significantly higher in C282Y heterozygous, H63D homozygous, and C282Y homozygous samples, in non-American laboratories, and in laboratories with lower testing volume. Analytical sensitivity and specificity were >98.5 and >99.5%. The interpretive error rate (4.3%) was higher than the genotyping error rate, with two problematic genotypes (C282Y heterozygous and H63D homozygous) accounting for 77% of total interpretive errors. There was a time-dependent improvement in the interpretation of the clinical significance of HFE genotypes.Conclusions:HFE molecular genetic testing, performed by non-US Food and Drug Administration-approved laboratory-developed tests, demonstrated excellent accuracy, sensitivity, and specificity. Clinical interpretations were more heterogeneous, probably owing to the low clinical penetrance of some common HFE genotypes.

Original languageEnglish (US)
Pages (from-to)1206-1213
Number of pages8
JournalGenetics in Medicine
Volume18
Issue number12
DOIs
StatePublished - Dec 1 2016

Fingerprint

Hemochromatosis
Genetic Testing
Molecular Biology
Genotype
Laboratory Proficiency Testing
Sensitivity and Specificity
Iron Overload
Penetrance
United States Food and Drug Administration
Pathologists
Surveys and Questionnaires

Keywords

  • Diagnostic errors
  • genetic testing
  • hemochromatosis
  • HFE
  • laboratory proficiency testing

ASJC Scopus subject areas

  • Genetics(clinical)

Cite this

Highly accurate molecular genetic testing for HFE hereditary hemochromatosis : Results from 10 years of blinded proficiency surveys by the College of American Pathologists. / Press, Richard; Eickelberg, Garrett; McDonald, Thomas J.; Halley, Jaimie; Long, Thomas; Tafe, Laura J.; Weck, Karen E.

In: Genetics in Medicine, Vol. 18, No. 12, 01.12.2016, p. 1206-1213.

Research output: Contribution to journalArticle

Press, Richard ; Eickelberg, Garrett ; McDonald, Thomas J. ; Halley, Jaimie ; Long, Thomas ; Tafe, Laura J. ; Weck, Karen E. / Highly accurate molecular genetic testing for HFE hereditary hemochromatosis : Results from 10 years of blinded proficiency surveys by the College of American Pathologists. In: Genetics in Medicine. 2016 ; Vol. 18, No. 12. pp. 1206-1213.
@article{607da7df24344439b117a0ad3ec330f8,
title = "Highly accurate molecular genetic testing for HFE hereditary hemochromatosis: Results from 10 years of blinded proficiency surveys by the College of American Pathologists",
abstract = "Purpose:The College of American Pathologists offers blinded proficiency testing (PT) for laboratories performing HFE genetic tests for hereditary hemochromatosis (common C282Y and H63D variants). This study used 10 years of PT data to determine laboratory performance for HFE analytical genotyping and clinical interpretation.Methods:Laboratories were graded for accuracy of genotype determination (six possible C282Y/H63D genotypes) and clinical interpretation regarding whether the genotype was likely to have contributed to iron overload in a hypothetical patient.Results:The analytical genotyping error rate was low (0.73{\%}) in 7,663 results (from 257 unique laboratories). Genotyping errors were significantly higher in C282Y heterozygous, H63D homozygous, and C282Y homozygous samples, in non-American laboratories, and in laboratories with lower testing volume. Analytical sensitivity and specificity were >98.5 and >99.5{\%}. The interpretive error rate (4.3{\%}) was higher than the genotyping error rate, with two problematic genotypes (C282Y heterozygous and H63D homozygous) accounting for 77{\%} of total interpretive errors. There was a time-dependent improvement in the interpretation of the clinical significance of HFE genotypes.Conclusions:HFE molecular genetic testing, performed by non-US Food and Drug Administration-approved laboratory-developed tests, demonstrated excellent accuracy, sensitivity, and specificity. Clinical interpretations were more heterogeneous, probably owing to the low clinical penetrance of some common HFE genotypes.",
keywords = "Diagnostic errors, genetic testing, hemochromatosis, HFE, laboratory proficiency testing",
author = "Richard Press and Garrett Eickelberg and McDonald, {Thomas J.} and Jaimie Halley and Thomas Long and Tafe, {Laura J.} and Weck, {Karen E.}",
year = "2016",
month = "12",
day = "1",
doi = "10.1038/gim.2016.34",
language = "English (US)",
volume = "18",
pages = "1206--1213",
journal = "Genetics in Medicine",
issn = "1098-3600",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Highly accurate molecular genetic testing for HFE hereditary hemochromatosis

T2 - Results from 10 years of blinded proficiency surveys by the College of American Pathologists

AU - Press, Richard

AU - Eickelberg, Garrett

AU - McDonald, Thomas J.

AU - Halley, Jaimie

AU - Long, Thomas

AU - Tafe, Laura J.

AU - Weck, Karen E.

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Purpose:The College of American Pathologists offers blinded proficiency testing (PT) for laboratories performing HFE genetic tests for hereditary hemochromatosis (common C282Y and H63D variants). This study used 10 years of PT data to determine laboratory performance for HFE analytical genotyping and clinical interpretation.Methods:Laboratories were graded for accuracy of genotype determination (six possible C282Y/H63D genotypes) and clinical interpretation regarding whether the genotype was likely to have contributed to iron overload in a hypothetical patient.Results:The analytical genotyping error rate was low (0.73%) in 7,663 results (from 257 unique laboratories). Genotyping errors were significantly higher in C282Y heterozygous, H63D homozygous, and C282Y homozygous samples, in non-American laboratories, and in laboratories with lower testing volume. Analytical sensitivity and specificity were >98.5 and >99.5%. The interpretive error rate (4.3%) was higher than the genotyping error rate, with two problematic genotypes (C282Y heterozygous and H63D homozygous) accounting for 77% of total interpretive errors. There was a time-dependent improvement in the interpretation of the clinical significance of HFE genotypes.Conclusions:HFE molecular genetic testing, performed by non-US Food and Drug Administration-approved laboratory-developed tests, demonstrated excellent accuracy, sensitivity, and specificity. Clinical interpretations were more heterogeneous, probably owing to the low clinical penetrance of some common HFE genotypes.

AB - Purpose:The College of American Pathologists offers blinded proficiency testing (PT) for laboratories performing HFE genetic tests for hereditary hemochromatosis (common C282Y and H63D variants). This study used 10 years of PT data to determine laboratory performance for HFE analytical genotyping and clinical interpretation.Methods:Laboratories were graded for accuracy of genotype determination (six possible C282Y/H63D genotypes) and clinical interpretation regarding whether the genotype was likely to have contributed to iron overload in a hypothetical patient.Results:The analytical genotyping error rate was low (0.73%) in 7,663 results (from 257 unique laboratories). Genotyping errors were significantly higher in C282Y heterozygous, H63D homozygous, and C282Y homozygous samples, in non-American laboratories, and in laboratories with lower testing volume. Analytical sensitivity and specificity were >98.5 and >99.5%. The interpretive error rate (4.3%) was higher than the genotyping error rate, with two problematic genotypes (C282Y heterozygous and H63D homozygous) accounting for 77% of total interpretive errors. There was a time-dependent improvement in the interpretation of the clinical significance of HFE genotypes.Conclusions:HFE molecular genetic testing, performed by non-US Food and Drug Administration-approved laboratory-developed tests, demonstrated excellent accuracy, sensitivity, and specificity. Clinical interpretations were more heterogeneous, probably owing to the low clinical penetrance of some common HFE genotypes.

KW - Diagnostic errors

KW - genetic testing

KW - hemochromatosis

KW - HFE

KW - laboratory proficiency testing

UR - http://www.scopus.com/inward/record.url?scp=85000502381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85000502381&partnerID=8YFLogxK

U2 - 10.1038/gim.2016.34

DO - 10.1038/gim.2016.34

M3 - Article

C2 - 27124787

AN - SCOPUS:85000502381

VL - 18

SP - 1206

EP - 1213

JO - Genetics in Medicine

JF - Genetics in Medicine

SN - 1098-3600

IS - 12

ER -